Pembrolizumab Combo Yields Significant OS in HER2+ Gastric/GEJ Cancer
The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.
The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.
Kim N. Chi, MD, FRCPC, discusses how the findings from the phase 3 MAGNITUDE trial translate into everyday practice.
WU-CART-007 has received RMAT and PRIME designations in relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
The gap in cancer mortality between Black and white individuals shrunk dramatically during the past 3 decades, according to a new report.However, racial and ethnic…
Mazyar Shadman, MD, MPH, details the efficacy of BTK inhibitors in the frontline treatment of CLL as well as safety considerations in the relapsed/refractory setting.
AbstractBackground:. Digital mammography has replaced film mammography in breast-screening programs globally, including Australia. This led to an increase in the rate of detection, but whether…
The James Cancer and Aging Resiliency (CARE) clinic is a leader in treating older cancer patients. Patients have been treated with blood and bone marrow…
Getting around MD Anderson doesn’t have to be overwhelming. We’re here to help you navigate your appointments. #Houston #Hospital #MDAnderson #MDAndersonCanc…
The FDA has approved one of the first HPV self-collection solutions, which can be used to identify women who are at risk of developing cervical…